Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013
Standard
Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013. / Hezel, M; Kurzweg, T; Münscher, A; Schafhausen, P; Knecht, R.
in: HNO, Jahrgang 61, Nr. 11, 01.11.2013, S. 911-3.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Konferenzaufsatz in Fachzeitschrift › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013
AU - Hezel, M
AU - Kurzweg, T
AU - Münscher, A
AU - Schafhausen, P
AU - Knecht, R
N1 - Leitthema, Zusammenfassung des ASCO 2013, Kongress-Nachschau
PY - 2013/11/1
Y1 - 2013/11/1
N2 - In many cases squamous cell carcinoma of the head and neck is already in an advanced stage when initially diagnosed. Despite definitive treatment, loco-regional recurrences and metastases are common and patients ultimately require systemic treatment. Epidermal growth factor receptor (EGFR) inhibitors have proven to significantly prolong survival and have therefore become the first line treatment in recurrent and metastatic squamous cell carcinoma of the head and neck in addition to platinum and 5-FU treatment. Good results have also been reported for EGFR inhibitors in cases where platinum-based treatment has failed. Further strategies, such as salvage surgery, platinum-based chemotherapy, targeted therapy, chemoradiation and reirradiation are currently under investigation to reduce toxicity and improve survival and health-related quality of life.
AB - In many cases squamous cell carcinoma of the head and neck is already in an advanced stage when initially diagnosed. Despite definitive treatment, loco-regional recurrences and metastases are common and patients ultimately require systemic treatment. Epidermal growth factor receptor (EGFR) inhibitors have proven to significantly prolong survival and have therefore become the first line treatment in recurrent and metastatic squamous cell carcinoma of the head and neck in addition to platinum and 5-FU treatment. Good results have also been reported for EGFR inhibitors in cases where platinum-based treatment has failed. Further strategies, such as salvage surgery, platinum-based chemotherapy, targeted therapy, chemoradiation and reirradiation are currently under investigation to reduce toxicity and improve survival and health-related quality of life.
U2 - 10.1007/s00106-013-2768-2
DO - 10.1007/s00106-013-2768-2
M3 - Konferenzaufsatz in Fachzeitschrift
C2 - 24221219
VL - 61
SP - 911
EP - 913
JO - HNO
JF - HNO
SN - 0017-6192
IS - 11
ER -